Article

Antheia has expanded its project agreement with the BioMaP-Consortium, obtaining an additional $9 million, bringing the total investment to $21 million. Funded by the U.S. Department of Health and Human Services' Defense Production Act Title III Program, this project aims to strengthen domestic pharmaceutical supply chains.

Antheia will utilize its biosynthesis platform to increase the commercial scale production of two vital pharmaceutical ingredients. The initiative is part of the U.S. government's efforts to enhance national health security and ensure the resilience of public health emergency responses.